Procter & Gamble Health Ltd. (PGHL) — Tipsheet

P&G Health's FY26 sales up 16%, profit up 30%; innovation and distribution gain

Tipsheet Editorial — Thu, 18 Jun 2026 16:00:48 GMT

Concall confirmed strong revenue and profit growth. New products beat expectations, distribution added 30k extra-urban pharmacies. No FY27 guidance but management sees sustained momentum.

What’s new

FY26 sales of ~₹1,400 cr (+16% YoY); PAT ₹327 cr (+30%).
Three new product launches beat expectations, contributing early single-digit growth.
Distribution added ~30,000 pharmacies in extra-urban areas over 2-3 years; Livogen Gummies hit #1 on Amazon.

Why it matters

The numbers confirm P&G Health's ability to drive profitable growth through innovation and distribution expansion, but the results were already disclosed. The concall adds color on execution, not new financials. At a P/E of 32x and ROE of 44%, the stock already prices in strong performance; the call reinforces the narrative.

What we’re watching

Whether innovation-led growth sustains without major new blockbusters.
Distribution expansion in extra-urban areas and its impact on margins.
Any future guidance on FY27 if market conditions change.

The full read

P&G Health's FY26 concall confirmed the already-reported numbers. Sales of ₹1,400 crore, up 16%; PAT of ₹327 crore, up 30%. No new financial data. But the call added detail: three new products (Livogen Iron Gummies, Neurobion Nerve Pain Cream, and Evion LC) all beat expectations and together contributed early single-digit growth points. Distribution added 30,000 extra-urban pharmacies over two to three years. E-commerce traction helped Livogen Gummies become Amazon's number-one seller. Management declined to guide for FY27 but cited strong fundamentals and the preventive-health shift. At 32x trailing earnings and a ₹10,487 cr market cap, the stock already reflects sustained execution. The call doesn't change the thesis: it confirms the story is playing out as planned.

Primary source: BSE · NSE

Procter & Gamble Health posts 30% profit growth for FY26

Tipsheet Editorial — Tue, 26 May 2026 17:31:59 GMT

The company closed the year with ₹327 crore in profit as Q4 momentum accelerated. Shareholders will receive a total dividend of ₹205 per share.

What’s new

FY26 sales reached ₹1,385 crore, up 16% year-on-year.
Q4 revenue rose 20% to ₹365 crore, with net profit jumping 55% to ₹95 crore.
The board declared a final dividend of ₹45 per share, totaling ₹205 for the year.

Why it matters

The results confirm a strong finish to the year, with Q4 growth outpacing the annual average. While the numbers were largely anticipated, the double-digit profit expansion demonstrates the effectiveness of recent brand investments.

What we’re watching

Whether the Q4 growth rate of 20% in revenue is sustainable into FY27.
The impact of further product innovations on operating margins.
Any shifts in consumer demand patterns in the coming quarters.

The full read

Procter & Gamble Health closed FY26 with ₹1,385 crore in sales and ₹327 crore in profit after tax. These figures represent growth of 16% and 30% respectively over the prior year. The momentum was particularly visible in the final quarter, where revenue climbed 20% to ₹365 crore and net profit jumped 55% to ₹95 crore. The board has recommended a final dividend of ₹45 per share, which brings the total annual payout to ₹205 per share. While these audited results confirm the company's trajectory, they were largely anticipated by the market following earlier disclosures. The primary takeaway is the acceleration in profitability during the final three months of the year, which suggests that recent brand investments and product launches are gaining traction with consumers. The company enters the new fiscal year with a clear trend of expanding margins.

Primary source: BSE · NSE

P&G Health's Q4 profit jumps 55% on strong pharma demand

Tipsheet Editorial — Tue, 26 May 2026 16:57:17 GMT

Annual net profit reached ₹327 crore. The board has declared a final dividend of ₹45 per share, taking the full-year payout to ₹205.

What’s new

Q4 revenue rose 19% year-on-year to ₹370 crore; net profit jumped 55% to ₹95 crore.
Full-year revenue was ₹1,408 crore with net profit of ₹327 crore.
Board recommended a final dividend of ₹45 per share, making the total FY26 dividend ₹205 per share.

Why it matters

P&G Health delivered a clean beat in the final quarter. The 55% profit jump on 19% sales growth points to improving profitability in its pharma portfolio. The unmodified audit opinion and the total dividend of ₹205 per share confirm a year of strong, unencumbered cash generation.

What we’re watching

Whether the 55% Q4 profit growth is sustainable into FY27 or driven by one-off demand.
Management commentary on pricing and input costs in the concall.
Any change in dividend payout ratio from the elevated FY26 level.

The full read

P&G Health closed a strong fiscal year. Q4 revenue hit ₹370 crore (+19% YoY), but the real story was profit, which jumped 55% to ₹94.60 crore. That spread between sales and profit growth points to improving margins in the pharma segment. For the full year, revenue reached ₹1,408 crore with net profit of ₹327 crore. The board has now declared a final dividend of ₹45 per share, bringing the total FY26 payout to ₹205 per share after earlier interim and special dividends. The audit came back clean, with an unmodified opinion. The results were largely expected, but they confirm that P&G Health is generating strong, growing cash flow for its owners.

Primary source: BSE · NSE